- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
13 result(s) found for: Mexiletine.
Displaying page 1 of 1.
EudraCT Number: 2019-003757-28 | Sponsor Protocol Number: MEX-NM-301 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Lupin Europe GmbH | |||||||||||||
Full Title: An Open-label, non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic Disorders | |||||||||||||
Medical condition: Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2); ICD-10 code G71.1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003758-97 | Sponsor Protocol Number: MEX-NM-303 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Lupin Europe GmbH | |||||||||||||
Full Title: Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed MEX-NM-301 and MEX-NM-302 Studies | |||||||||||||
Medical condition: Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2); ICD-10 code G71.1 | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024026-38 | Sponsor Protocol Number: mex201011 | Start Date*: 2012-01-10 |
Sponsor Name:Radboud University Nijmegen Medical Center | ||
Full Title: Combining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia. | ||
Medical condition: Patients with non-dystrophic myotonic syndromes (NDMs). NDMs are caused by mutations in the gene encoding for the skeletal muscle sodium (SCN4A) or chloride (CLCN1) channel. In this study patient... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011184-36 | Sponsor Protocol Number: 08/0169 | Start Date*: 2009-07-14 | |||||||||||
Sponsor Name:University College London-Joint UCLH/UCL Biomedical (R&D) Unit | |||||||||||||
Full Title: A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia. | |||||||||||||
Medical condition: Non-Dystrophic Myotonia (NDM). Non-dystrophic myotonias are a group of rare neuromuscular disorders that cause episodes of muscle stiffness (known as myotonia) and paralysis. Predominantly the musc... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002627-10 | Sponsor Protocol Number: RILUMEX | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | |||||||||||||
Full Title: A randomized, double-blind, controlled, monocenter, pivotal phase IIb study to evaluate the efficacy and safety of riluzole versus mexiletine in patients with non dystrophic myotonia mutated in SCN... | |||||||||||||
Medical condition: NDM patients with mutations in SCN4A or CLCN1 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001287-22 | Sponsor Protocol Number: FLECAINIDE-1 | Start Date*: 2011-04-18 | |||||||||||
Sponsor Name:FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE | |||||||||||||
Full Title: A Prospective Randomized Crossover trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia | |||||||||||||
Medical condition: Patients with CPVT and ICD | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006652-22 | Sponsor Protocol Number: AN08/8751 | Start Date*: 2009-06-03 |
Sponsor Name:Leeds Teaching Hospital NHS Trust | ||
Full Title: A multicentre, randomised, double blind, evaluative comparison trial of Rapydan® patch and Ametop® gel for topical anaesthesia during venous cannulation in adults admitted to hospital for day-case ... | ||
Medical condition: ASA 1 and 2 patients admitted for Day case surgery- assessment of cannulation pain after topical anaesthetic applications. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020923-37 | Sponsor Protocol Number: P091101 | Start Date*: 2010-10-26 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude de l'efficacité et de la tolérance de la mexiletine dans les myotonies non dystrophiques | |||||||||||||
Medical condition: Patients présentant une myotonie non-dystrophique de type myotonie congénitale (MC) ou paramyotonie congénitale (PM). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000042-30 | Sponsor Protocol Number: GS-US-372-1234 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome | |||||||||||||
Medical condition: Subjects with an established diagnosis of LQT3. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004007-19 | Sponsor Protocol Number: AV-007-IM | Start Date*: 2006-11-16 | |||||||||||
Sponsor Name:Nycomed Austria GmbH | |||||||||||||
Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group clinical trial to evaluate efficacy and safety of Actovegin® in diabetic type 2 patients with symptomatic diabetic perip... | |||||||||||||
Medical condition: Diabetic Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010091-17 | Sponsor Protocol Number: KIP112967 | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury. Estudio aleatorizado, do... | |||||||||||||
Medical condition: Neuropathic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002846-21 | Sponsor Protocol Number: PARENTIDE-02 | Start Date*: 2017-04-10 |
Sponsor Name:BCN Peptides S.A. | ||
Full Title: CLINICAL TRIAL PHASE IIa PROOF OF CONCEPT, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED IN PATIENTS WITH NEUROPATHIC PAIN DUE TO PERIPHERAL NERVE INJURY | ||
Medical condition: Patients with neuropathic pain due to peripheral nerve injury | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-003784-94 | Sponsor Protocol Number: MexLam | Start Date*: 2022-01-20 | ||||||||||||||||
Sponsor Name:Rigshospitalet, department of Neurology | ||||||||||||||||||
Full Title: Treatment of Myotonia - Lamotrigine versus Namuscla | ||||||||||||||||||
Medical condition: Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
